Etanercept NSAIDs

Based on the bio-molecular pathogenesis, novel therapeutic agents have been developed since 1998 for the treatment of DMARDs refractory autoimmune diseases. These biological-DMARDs include infliximab, etanercept, adalimumab, rituximab and abatacept. The biological-DMARDs anti TNF-a were first approved for therapy of refractory RA, followed by Crohn s disease, AS, and PsA. Scores of other biological DMARDs in Phase I, II, and III clinical trials in autoimmune diseases indicate that the number of these biological agents may ultimately become equal to the number of NSAIDs introduced over the last 50 years. 

Drugs are common causes of vasculitis, often occurring in the skin, but other organ involvement can occur. The pathogenesis of inflammation of small and medium-sized blood vessel walls caused by drugs is poorly understood. Even drugs used to treat inflammatory and immune-mediated disease, such as NSAIDs, sulfasalazine, and etanercept, can cause vasculitis. 

---